| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement
|
|
|
2012
|
|
6 |
p. 361
|
artikel
|
| 2 |
Acknowledgement to Referees
|
|
|
2013
|
|
6 |
p. 339-340
|
artikel
|
| 3 |
Acknowledgement to Referees
|
|
|
2016
|
|
6 |
p. 313-316
|
artikel
|
| 4 |
Acknowledgement to Referees
|
|
|
2014
|
|
6 |
p. 303-304
|
artikel
|
| 5 |
Acknowledgement to Referees
|
|
|
2017
|
|
6 |
p. 375-377
|
artikel
|
| 6 |
Acknowledgement to Referees
|
|
|
2015
|
|
6 |
p. 313-314
|
artikel
|
| 7 |
Acknowledgement to Referees
|
|
|
2018
|
|
6 |
p. 383-386
|
artikel
|
| 8 |
Acknowledgement to referees
|
|
|
|
|
6 |
p. 441-444
|
artikel
|
| 9 |
Adulterants and Contaminants in Psychotropic Herbal Medicines Detected with Mass Spectrometry and Next-Generation DNA Sequencing
|
Hoban, Claire L.
|
|
2018
|
|
6 |
p. 429-444
|
artikel
|
| 10 |
Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
|
Stergiopoulos, Stella
|
|
|
|
6 |
p. 499-510
|
artikel
|
| 11 |
Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
|
Stergiopoulos, Stella
|
|
|
|
6 |
p. 499-510
|
artikel
|
| 12 |
Adverse Drug Reaction Onsets in Uganda’s VigiBase®: Delayed International Visibility, Data Quality and Illustrative Signal Detection Analyses
|
Kiguba, Ronald
|
|
2018
|
|
6 |
p. 413-427
|
artikel
|
| 13 |
Analysis of Low Molecular Weight Substances and Related Processes Influencing Cellular Cholesterol Efflux
|
Litvinov, Dmitry Y.
|
|
|
|
6 |
p. 465-498
|
artikel
|
| 14 |
Analysis of Low Molecular Weight Substances and Related Processes Influencing Cellular Cholesterol Efflux
|
Litvinov, Dmitry Y.
|
|
|
|
6 |
p. 465-498
|
artikel
|
| 15 |
Apothecaries’ Hall—Promoting the History, Philosophy, and Ethics of Medicine and Pharmacy for 60 Years
|
Snell, Noel
|
|
|
|
6 |
p. 449
|
artikel
|
| 16 |
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
|
Albhaisi, Somaya
|
|
|
|
6 |
p. 451-463
|
artikel
|
| 17 |
Assessing Psychiatric Adverse Effects during Clinical Drug Development
|
Rudorfer, Matthew V.
|
|
2012
|
|
6 |
p. 363-394
|
artikel
|
| 18 |
Assessment of Postmarketing Safety-Related Regulatory Actions in Japan
|
Ogami, Tetsuro
|
|
2012
|
|
6 |
p. 395-403
|
artikel
|
| 19 |
A Systematic Scoping Review of the State of Pharmacovigilance and Governance in the MENA Region: Challenges and Opportunities
|
Hamid, Abeer Abdullah
|
|
2017
|
|
6 |
p. 437-454
|
artikel
|
| 20 |
Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
|
Krentz, Andrew J.
|
|
2017
|
|
6 |
p. 399-421
|
artikel
|
| 21 |
Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer
|
Barron, Anthony
|
|
2016
|
|
6 |
p. 321-326
|
artikel
|
| 22 |
Current Landscape of Late-Phase Clinical Trials for Alzheimer’s Disease: Comparing Regional Variation Between Subjects in Japan and North America
|
Kikuchi, Masashi
|
|
|
|
6 |
p. 511-518
|
artikel
|
| 23 |
Data Mining of the US FDA’s Adverse Events Reporting System Database to Evaluate Drug–Drug Interactions Associated with Statin-Induced Rhabdomyolysis
|
Muñoz, Monica A.
|
|
2016
|
|
6 |
p. 327-337
|
artikel
|
| 24 |
Delays in New Drug Applications and Associated Factors for Orphan Anticancer Drugs in Japan Compared with the USA
|
Nakayama, Hiroki
|
|
2018
|
|
6 |
p. 403-412
|
artikel
|
| 25 |
Drugs in Clinical Development for Duchenne Muscular Dystrophy: Summary and Table
|
|
|
2014
|
|
6 |
p. 329-331
|
artikel
|
| 26 |
Drugs in Clinical Development for Fungal Infections: Summary and Table
|
|
|
2015
|
|
6 |
p. 361-363
|
artikel
|
| 27 |
Drugs in Clinical Development for Multiple Myeloma: Summary and Table
|
|
|
2013
|
|
6 |
p. 353-370
|
artikel
|
| 28 |
Drugs in Clinical Development for Obesity
|
|
|
2012
|
|
6 |
p. 405-410
|
artikel
|
| 29 |
Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French
|
Villeneuve, Claire
|
|
2017
|
|
6 |
p. 455-465
|
artikel
|
| 30 |
Forum
|
|
|
2013
|
|
6 |
p. 371-377
|
artikel
|
| 31 |
Forum
|
|
|
2016
|
|
6 |
p. 349-363
|
artikel
|
| 32 |
Forum
|
|
|
2014
|
|
6 |
p. 333-341
|
artikel
|
| 33 |
Forum
|
|
|
2017
|
|
6 |
p. 467-492
|
artikel
|
| 34 |
Forum
|
|
|
2015
|
|
6 |
p. 365-374
|
artikel
|
| 35 |
Forum
|
|
|
2012
|
|
6 |
p. 411-420
|
artikel
|
| 36 |
Forum
|
|
|
2018
|
|
6 |
p. 445-457
|
artikel
|
| 37 |
Forum
|
|
|
|
|
6 |
p. 531-540
|
artikel
|
| 38 |
Global Implications of the EU’s Pharmacovigilance System Master File Requirements: Newly Developed Decision Trees to Distinguish Different Study Types
|
Kaehler, Stefan T.
|
|
2015
|
|
6 |
p. 323-329
|
artikel
|
| 39 |
Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US
|
Bahk, Chi Y.
|
|
2015
|
|
6 |
p. 331-340
|
artikel
|
| 40 |
Journal Watch
|
|
|
2014
|
|
6 |
p. 343-352
|
artikel
|
| 41 |
Journal Watch
|
|
|
2012
|
|
6 |
p. 421-429
|
artikel
|
| 42 |
Journal Watch
|
|
|
2013
|
|
6 |
p. 379-388
|
artikel
|
| 43 |
Major Pharmaceutical Conferences and Courses
|
|
|
2013
|
|
6 |
p. 389-393
|
artikel
|
| 44 |
Major Pharmaceutical Conferences and Courses
|
|
|
2016
|
|
6 |
p. 365-368
|
artikel
|
| 45 |
Major Pharmaceutical Conferences and Courses
|
|
|
2014
|
|
6 |
p. 353-358
|
artikel
|
| 46 |
Major Pharmaceutical Conferences and Courses
|
|
|
2017
|
|
6 |
p. 493-495
|
artikel
|
| 47 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015
|
|
6 |
p. 375-378
|
artikel
|
| 48 |
Major Pharmaceutical Conferences and Courses
|
|
|
2012
|
|
6 |
p. 431-434
|
artikel
|
| 49 |
Major Pharmaceutical Conferences and Courses
|
|
|
2018
|
|
6 |
p. 459-462
|
artikel
|
| 50 |
Major Pharmaceutical Conferences and Courses
|
|
|
|
|
6 |
p. 541-543
|
artikel
|
| 51 |
Medicines Regulation in Africa: Current State and Opportunities
|
Ndomondo-Sigonda, Margareth
|
|
2017
|
|
6 |
p. 383-397
|
artikel
|
| 52 |
Periodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective
|
Arlett, Peter
|
|
2014
|
|
6 |
p. 309-315
|
artikel
|
| 53 |
Public Knowledge and Desire for Knowledge about Drug Safety Issues: A Survey of the General Public in New Zealand
|
Maclennan, Karyn
|
|
2016
|
|
6 |
p. 339-348
|
artikel
|
| 54 |
Second Meeting of the Global Forum on Bioethics in Research
|
Crawley, Francis P.
|
|
|
|
6 |
p. 333-334
|
artikel
|
| 55 |
Strengthening the Cost Effectiveness of Medical Countermeasure Development Against Rare Biological Threats: The Ebola Outbreak
|
Johnson, Mark Lawrence
|
|
2017
|
|
6 |
p. 423-436
|
artikel
|
| 56 |
The Contrasting Medicines Regulatory Environments of China and the Western World
|
Harris, Peter J.
|
|
2015
|
|
6 |
p. 319-322
|
artikel
|
| 57 |
The Emergence of Regulatory Science in Pharmaceutical Medicine
|
Callréus, Torbjörn
|
|
2013
|
|
6 |
p. 345-351
|
artikel
|
| 58 |
The Impact of Nonadherence to Inhaled Long-Acting β2-Adrenoceptor Agonist/Corticosteroid Combination Therapy on Healthcare Costs in Difficult-to-Control Asthma
|
O’Neill, Ciaran
|
|
2011
|
|
6 |
p. 379-385
|
artikel
|
| 59 |
The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval
|
Martín-Merino, Elisa
|
|
|
|
6 |
p. 519-530
|
artikel
|
| 60 |
The Pharmaceutical Year That Was, 2013
|
Fox, Anthony W.
|
|
2013
|
|
6 |
p. 341-344
|
artikel
|
| 61 |
The Pharmaceutical Year that was, 2016
|
Fox, Anthony W.
|
|
2016
|
|
6 |
p. 317-319
|
artikel
|
| 62 |
The Pharmaceutical Year That Was, 2014
|
Fox, Anthony W.
|
|
2014
|
|
6 |
p. 305-307
|
artikel
|
| 63 |
The Pharmaceutical Year That Was, 2017
|
Fox, Anthony W.
|
|
2017
|
|
6 |
p. 379-382
|
artikel
|
| 64 |
The Pharmaceutical Year That Was, 2015
|
Fox, Anthony W.
|
|
2015
|
|
6 |
p. 315-318
|
artikel
|
| 65 |
The Pharmaceutical Year That Was, 2018
|
Fox, Anthony W.
|
|
2018
|
|
6 |
p. 387-389
|
artikel
|
| 66 |
The Pharmaceutical Year That Was, 2019
|
Fox, Anthony W.
|
|
|
|
6 |
p. 445-447
|
artikel
|
| 67 |
The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond
|
Sellers, Edward M.
|
|
2014
|
|
6 |
p. 317-327
|
artikel
|
| 68 |
Training Augmented Intelligent Capabilities for Pharmacovigilance: Applying Deep-learning Approaches to Individual Case Safety Report Processing
|
Abatemarco, Danielle
|
|
2018
|
|
6 |
p. 391-401
|
artikel
|
| 69 |
Untangling the Complexity of Funding Recommendations: A Comparative Analysis of Health Technology Assessment Outcomes in Four European Countries
|
Cerri, Karin H.
|
|
2015
|
|
6 |
p. 341-359
|
artikel
|
Tijdschrift beschrijving